ACC 2019Annabelle Volgman discusses the results of the Apple Heart Study. This trial examined whether wearable technology can be used to detect AF in asymptomatic individuals to prevent stroke.

ACC 2019 Previous results have shown benefits in mortality and HF hospitalization with MitraClip. New data complement the previous findings and demonstrate improved quality of life with MitraClip in HF patients with secondary MR.

ACC 2019 In the MOMENTUM 3 trial, the centrifugal-flow pump HeartMate 3 was compared with the axial-flow pump HeartMate 2 in patients with advanced HF. Prof. Uriel discusses the findings and implications of this trial.

ACC 2019 The COACT trial examined whether NSTEMI patients had a better survival after cardiac arrest using immediate coronary angiography vs. delayed strategy.

ACC 2019 In diabetes patients, use of dapagliflozine resulted in clinical benefit regardless of ejection fraction and CV death and total mortality were strongly reduced in HFrEF patients.

ACC 2019 Pulmonary artery pressure-guided therapy in class III HF patients met the primary efficacy and two safety endpoints at 1 year in the CardioMEMS trial.

ACC 2019 Previously, short-term results of the POET trial were presented. Now, long-term data confirmed that oral antibiotics are as safe and effective as IV treatment in patients with left-sided endocarditis.

ACC 2019 In an echocardiography substudy of the COAPT trial, predictors of poor outcomes were studied in HF patients with severe secondary mitral regurgitation.

ACC 2019 An open-label extension study of the PIONEER-HF trail showed that in-hospital initiation of sacubitril/valsartan (S/V) improved clinical outcomes after ADHF among HFrEF patients, compared to in-hospital initiation of enalapril followed by S/V.

ACC 2019 The randomized INFINITY trial showed a significant reduction in accrual of subcortical white matter disease in older people receiving more intensive antihypertensive therapy, but mobility and cognitive function were not improved.

ACC 2019 Post-approval analyses of the CardioMEMS PAS trial showed that adapting therapy based on pulmonary artery pressure is effective in reducing hospitalizations for HF and safe in patients with NYHA class III HF.

ACC 2019 The COACT trial did not show improved survival at 90 days with immediate vs. delayed coronary angiography in NSTEMI patients with return of spontaneous circulation after out-of-hospital cardiac arrest.